LARS1 and malaria: Moreover, the YRS inhibitor ML901, exhibits whole-life-cycle killing activity in a mouse model of malaria (Xie et al., 2022), and the LRS inhibitor GSK656, has been used in clinical trials for systemic use against tuberculosis (Tenero et al., 2019).